Inflammatory signals from the surrounding microenvironment play important roles in tumor promotion. Key inflammatory mediators and pathways that induce and sustain tumorigenesis have recently been identified in many different cancers. Hepatocellular carcinoma is a paradigm for inflammation-induced cancer, since it most frequently develops on grounds of chronic hepatitis, consecutive cellular damage and compensatory regeneration. Recent studies revealed that liver damage-mediated inflammation and carcinogenesis is triggered by a complex crosstalk between NFB, JNK and Stat3 signaling pathways. Molecular dissection of the mechanisms involved in the interplay between these pathways identified promising new targets for therapeutic intervention. Targeting different components of the signaling cascades may provide efficient means for blocking the apparently irreversible sequence of events initiated by chronic liver inflammation culminating in liver cancer.
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More than 90% of the HCC cases are associated with chronic inflammation, which arises from hepatitis B virus (HBV), hepatitis C virus (HCV) infection, hemochromatosis and alcoholic or non-alcoholic steatosis (3) . Recent studies on mouse models provided important mechanistic insights into the pathogenesis by revealing the role of multiple signaling pathways that link chronic inflammation to HCC. These include the nuclear factor-B (NFB), the stress-responsive mitogen-activated protein kinase (MAPK) and the signal transducer and activator of transcription (STAT) pathways. Importantly, it was shown that these signaling pathways are linked to each other in a highly regulated manner, forming a highly complex signaling network that allows quality control and extensive communication between inflammatory cells and hepatocytes.
Interplay between NFB and JNK signaling pathway
The NFB family consists of five transcription factors, p50, p52, p65, cRel and RelB, which share an N-terminal Rel-homology DNA binding and dimerization domain (4) . NFB homo and heterodimers are sequestered in the cytoplasm via non-covalent interactions with IB proteins (Figure 1 , red symbols and arrows). Upon stimulation, I is phosphorylated by the I Kinase (IKK) complex, which consists of the IKK and IKKcatalytic and the IKK/NEMO regulatory subunit (4, 5) . Phosphorylation of Is results in their K48-linked ubiquitination and subsequent degradation by the 26S proteasome complex (6) . The free NF dimmers can then translocate to the nucleus and activate the transcription of genes encoding cytokines, chemokines and anti-apoptotic factors that promote cell growth and survival (7) . NF is also a potent inducer of the caspase 8 homologue FLICE-interacting protein (cFLIP) a repressor of death receptor-induced apoptosis ( Figure 1 , red arrows) (8) .
The NF pathway is activated by various stimuli including LPS, and anti-inflammatory cytokines, like tumor necrosis factor (TNF) and interleukin-1 (IL-1), which elicit their effects through binding to Toll-like receptors (TLRs) and to the TNF or IL-1 receptors (4, 9) . These cytokines are produced by inflammatory cells, which accumulate in the liver upon virus infection-induced hepatitis or through the action of other causative agents of inflammation. Upon stimulation by the corresponding ligands, rapid assembly of complexes containing TRADD, TRAF and RIP1 proteins occur at the TLR/IL-R or TNFR, which recruit and activate TAK1 through TRAF6 or TRAF2, respectively. TAK1 subsequently phosphorylate IKK and MKK4/7, which in turn activate NF and JNK, respectively (10-12) (Figure 1 ). The assembly step of activated receptor complexes involves TRAF2 and cIAP1/2-mediated K63-linked ubiquitination of several of the components, including TRAF2, TRAF6, TAK1, RIP1 and NEMO, which facilitates protein-protein interactions and the assembly of the signalling complexes (10) (11) (12) (13) (14) . The main enzyme that removes poly-ubiquitin chains from the above proteins is the cylindromatosis tumor suppressor Cyld (15) (16) (17) (18) (19) (20) . As a result of Cyld-mediated deubiquitination of TAK1 and other components of the complex, NF signalling is inhibited. Importantly, the Cyld gene is transcriptionally activated by NF, which provides a negative feedback regulatory loop that could function in balancing activated NF levels (21) (Figure 1 ).
While F activation has pro-survival, anti-apoptotic effects, JNK signalling ( Figure 1 , green symbols and arrows) has been implicated in the induction of either cell proliferation or apoptosis (22) (23) (24) . JNK can phosphorylate various substrates, including c-Jun, JunB, JunD ATF2, p53, Bcl2, Bcl-xL, Bid, Bad and Bax proteins, which regulate cell growth and death (25) . One mechanism by which JNK contributes to cell survival involves JunD phosphorylation, which transcriptionally activates anti-apoptotic genes ( Figure 1 animal models. NF seems to have a pro-tumorigenic effect in Mdr2-/-mice, which exhibit low-grade chronic inflammation and spontaneous development of HCC (37) . Inhibition of the NF pathway by the expression of non-degradable I mutant prevented HCC formation and increased apoptosis of premalignant hepatocytes (38) . Similar protective effects were observed after the administration of anti-inflammatory or anti-TNF drugs to Mdr2-deficient mice. Transgenic mice expressing lymphotoxins  and  (Lt) in the liver display inflammation, fibrosis and develop HCC (39) . In this model the occurrence of inflammation and HCC depends on IKK expression in hepatocytes, but is independent of TNFR1 function (39) .
In sharp contrast to the above pro-tumorigenic effects, NF signalling exhibits a tumor suppressor function in situations when liver inflammation is mainly driven by hepatocyte damage. For example, mice lacking IKK in hepatocytes exhibit a marked increase in hepatocarcinogenesis after diethylnitrosamine (DEN) treatment (40) (41) (42) . In this experimental condition, hepatocyte-specific IKK depletion enhanced ROS production, induced JNK activation and hepatocyte death, which augmented compensatory proliferation of surviving hepatocytes. Hepatocyte death-mediated accumulation of inflammatory cells, including the activation of resident macrophages (Kupffer cells), was necessary for the carcinogenesis process (40) . This was revealed by the observation of decreased hepatocarcinogenesis in mice where IKK was deleted in both hepatocytes and Kupffer cells (40) . Since Kupffer cell activation could not take place in the absence of NF, the above results suggest that the NF pathway coordinates the inflammatory crosstalk between hepatocytes and Kupffer cells (Figure 2 ). Hepatocyte specific inactivation of NEMO (IKK) or TAK1, the upstream activators of NF, resulted in spontaneous hepatocyte death, liver inflammation, fibrosis and the development of HCC (43) (44) (45) . Interestingly, constitutive hyperactivation of TAK1 in Cyld-deficient hepatocytes displayed similar effects (46) . Taken Phospho-Stat3 translocates to the nucleus and activates numerous oncogenic genes, resulting in enhanced hepatocyte proliferation (Figure 2) (42, 49) . In human HCC samples there is an inverse correlation between NF and Stat3 signaling (42, 50, 51) . The underlining mechanism involves feedback inhibition of STAT3 activation via tyrosine phosphatases, like SHP1/2 and SOCS3. In this pathway elevated ROS levels generated by NF inhibition oxidize SHP1/2. Oxidized SHP1/2 loose their enzymatic activity towards JAK2 substrate, which leads to constitutive activation of the JAK-STAT3 pathway (52) (Figure 2 
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Collectively the above findings establish the view of a complex interplay between different signalling pathways that regulate distinct phases during the pathogenesis of inflammation-associated hepatocellular carcinoma. This "interpathway crosstalk" is accomplished through various feed-forward, feedback and autoregulatory loops that operate not only within individual cells, but also between inflammatory cells and hepatocytes.
Clinical-Translational Advances
Due to the impaired liver function of HCC patients, classical anti-cancer chemotherapeutics are toxic and ineffective. The recently introduced Sorfenib is a tyrosine kinase inhibitor, targeting multiple molecular pathways. Although its superior efficacy over conventional chemotherapy has been established by two large-scale clinical trials, its overall value is considered low, as it improves median life expectancy by only 3 months over placebo (53, 54) . While combination of sorfenib with cytotoxic (e.g. Doxorubicin) or anti-angiogenic (eg. VEGF inhibitors) agents is being evaluated, to date there is no evidence for the potential of the currently used therapeutics to shrink cancerous lesions or to prevent cancer formation.
This gives emphasis to the urgent demand for alternative approaches.
The main translational benefit of studies that established an unambiguous connection between chronic inflammation and HCC is the recognition of an increased repertoire of promising new targets for the development of effective systemic therapies of HCC. An important preventive approach is the treatment with antiviral drugs against HBV and HCV, which would eliminate the main ground on which HCC develops. Unfortunately, despite extensive efforts using antiviral therapies, it is currently not possible to cure chronic viral hepatitis. The use of other anti-inflammatory drugs (e.g. non-steroidal compounds, like aspirin) has proven effective in other cancer types, but has not been evaluated in HCC. Targeting the NF pathway emerges as an alternative concept for curing HCC, given its central position in the regulation of inflammatory processes. Several observations in different mouse models that can be recapitulated in human HCCs, point to the feasibility of pharmacological targeting of NFB and NFB-linked signalling pathways. In the majority of human subjects, where HCC was preceded by chronic HBV or HCV-mediated inflammation, the mechanism of disease progression resembles that described in Mdr2 KO mice or Lttransgenic mice, where NF function is absolutely required (37) (38) (39) . In these cases blocking the NF pathway (e.g. by IKK inhibitors), may have beneficial effects. In the cases where HCC develops on the ground of hepatocyte damage (e.g. in alcoholic or nonalcoholic steatohepatitis or after chronic toxic assaults), the situation is more complex.
Interpreting the data from the animal models where HCC is initiated by hepatocyte death raise arguments against the feasibility of using IKK inhibitors for treatment, because inactivation of different components in the pathway (IKK, NEMO or TAK1) actually promote carcinogenesis (see above). Importantly however, HCC development is halted when IKKis simultaneously ablated in hepatocytes and Kupffer cells, a situation that is more likely mimicked by systemic inhibitor treatment (40) . On this conceptual basis, IKK inhibitors can be considered good candidates for HCC treatment and definitely warrant additional studies. In this regard we note that the extent of inhibition of the individual components should be taken into account, as they may greatly affect the final outcome. In genetic models the inhibition of the pathway is nearly complete, while in the case of treatment with pharmacological inhibitors the extent of blockage is partial and in most cases adjustable. homeostasis (46) . Additional studies on its ubiquitination-mediated regulation would be important to learn more about this enzyme, since, in addition to NF, it can also activate the JNK pathway, which seems to represent a highly promising target for anticancer therapy.
The role of sustained JNK activation in hepatocyte death and subsequent inflammation and carcinogenesis is recapitulated in most of the mouse genetic models (IKK-KO, NEMO-KO, TAK1-KO and Cyld-KO) developing HCC (40) (41) (42) (43) (44) (45) (46) . In addition, mice expressing hepatitis C virus core protein activate JNK through ROS production (55). Importantly, JNK1 is phosphorylated in human HCC samples (56). Direct evidence for the idea that JNK could be a promising drug target was provided by the findings that administration of the JNK inhibitor SP600125 to Cyld-deficient mice or DEN-treated rats blocked the development of HCC (46, 57). SP600125 has also been shown to sensitize tumor cells, but not normal hepatocytes to TRAIL, a major mediator of acquired immune tumour surveillance (58). Thus, JNK inhibitors that also sensitize TRAIL could be used in combination with TRAIL-targeting drugs to increase therapeutic efficiency.
The other potential target presented in this review is STAT3. In mice, prevention of STAT3 activation via inhibition of its upstream kinase JAK2 was found to be effective in blocking HCC development (42) . STAT3 was detected in its activated form in more than 60% of human HCC samples and phosphorylated STAT3 levels correlated with the aggressiveness of the tumours (42) . Importantly, STAT3 deletion does not affect the survival of differentiated cells, but efficiently blocks cell proliferation, suggesting that STAT3 may be a safe target for cancer therapeutics.
Taken together, studies on mouse models have revealed a complex crosstalk between NF, JNK and STAT3 signaling pathways in inflammation-associated HCC. These studies have provided novel insights into the temporal order of regulated steps during the pathogenesis, which raise the possibility of developing novel means to block the sequence of events that lead to HCC. Successful translation of the knowledge gained on NF, JNK and STAT3 signaling will depend on appropriate human studies that would motivate the development of safer and more effective cancer therapies.
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